Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma
- PMID: 17420990
- DOI: 10.1002/pbc.21195
Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma
Abstract
Background: MYCN amplification marks poor prognosis in neuroblastoma (NB) tumors. In evaluating the mechanisms by which retinoic acid (RA) or nerve growth factor (NGF) decrease cell number in MYCN amplified NB cells, we have identified a number of proteins whose expression either decreases (E2F, CDC2, CDK6, cyclin dependent kinase activity) or increases (p27) in association with a decrease in MYCN expression. However, it was still unclear which were MYCN dependent effects or not.
Procedure: This study aimed to determine which changes in cell cycle gene expression are modulated as a consequence of the decrease in MYCN. We silenced MYCN expression using siRNA _targeted to the coding region of MYCN. Then, by using siRNA transient transfections, we analyzed the change of cell cycle related genes and cell cycle in MYCN amplified NB cell lines.
Results: We demonstrate that expression of MYCN can be suppressed by almost 60% in MYCN amplified NB cell using siRNAs _targeted to MYCN. Functionally, the decrease in MYCN leads to a decrease in cells in the S-phase of the cell cycle. Decreases in MYCN are associated with decreases in E2F1-2 and ID2 along with increases in p27 protein levels by post-transcriptional modification. Moreover, we find that a decrease in MYCN is accompanied by a decrease in cdk6 mRNA and protein expression.
Conclusions: These results show that E2F and ID2 expression is associated with MYCN regulation and that cdk6 is a possible new transcriptional _target of MYCN.
(c) 2007 Wiley-Liss, Inc.
Similar articles
-
Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.Int J Oncol. 2008 Nov;33(5):1081-9. Int J Oncol. 2008. PMID: 18949372
-
Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification.Int J Oncol. 2007 May;30(5):1189-96. Int J Oncol. 2007. PMID: 17390021
-
Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.Cancer Res. 2010 May 1;70(9):3791-802. doi: 10.1158/0008-5472.CAN-09-1245. Epub 2010 Apr 27. Cancer Res. 2010. PMID: 20424123
-
MDM2 as MYCN transcriptional _target: implications for neuroblastoma pathogenesis.Cancer Lett. 2005 Oct 18;228(1-2):21-7. doi: 10.1016/j.canlet.2005.01.050. Cancer Lett. 2005. PMID: 15927364 Review.
-
MYCN oncoprotein _targets and their therapeutic potential.Cancer Lett. 2010 Jul 28;293(2):144-57. doi: 10.1016/j.canlet.2010.01.015. Epub 2010 Feb 13. Cancer Lett. 2010. PMID: 20153925 Review.
Cited by
-
Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19190-5. doi: 10.1073/pnas.1208215109. Epub 2012 Oct 22. Proc Natl Acad Sci U S A. 2012. PMID: 23091029 Free PMC article.
-
p53, SKP2, and DKK3 as MYCN _target Genes and Their Potential Therapeutic Significance.Front Oncol. 2012 Nov 28;2:173. doi: 10.3389/fonc.2012.00173. eCollection 2012. Front Oncol. 2012. PMID: 23226679 Free PMC article.
-
Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop.Onco_target. 2010 Aug;1(4):278-288. doi: 10.18632/onco_target.138. Onco_target. 2010. PMID: 21304178 Free PMC article.
-
Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular _targets for precision interventions.Front Cell Dev Biol. 2024 Mar 27;12:1353860. doi: 10.3389/fcell.2024.1353860. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38601081 Free PMC article. Review.
-
MYCN, neuroblastoma and focal adhesion kinase (FAK).Front Biosci (Elite Ed). 2011 Jan 1;3(2):421-33. doi: 10.2741/e257. Front Biosci (Elite Ed). 2011. PMID: 21196322 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous